TCM formula granule VBP brings challenge for company, but it also brings hope. There're breakthrough point of CAR-T's price decline. Gan & Lee has recovered from VBP, with further rebound ahead
What is covered in the Full Insight:
Performance Analysis of TCM Formula Granule Enterprises
Challenges and Progress in CAR-T Therapy
Overview of Gan & Lee Pharmaceuticals’ Core Insulin Business
Market Review
Risk Disclosure
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.